Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

The new financial backing – which includes a buy-in from Sanofi – will be used to help ... to respond could allow for targeted use immuno-oncology drugs, potentially saving healthcare systems ...

It also includes the termination fee for other drugs under the original immune-oncology agreement. Sanofi can opt in to development of the bispecific antibodies codenamed BCMAxCD3 and MUC16xCD3 ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...

Sanofi (NASDAQ:SNY) is a global healthcare company headquartered in Paris, France. It specializes in medical treatments for ...

Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.

In striving to become the number one immunoscience company globally, Sanofi remains committed to advancing oncology innovation. Through focused strategic decisions the company has reshaped and ...

The outcomes from the Phase III IMROZ study support the decision. Sanofi Oncology global head Olivier Nataf stated: “In recent years, new multiple myeloma cases have increased steadily in Japan ...